Table 1.

Select ongoing novel chimeric antigen receptor T-cell trials

TargetPhaseIdentifierAdditional agents
CD19/CD20 NCT04215016
NCT04007029 
 
CD19/CD22 NCT03233854  
CD19/CD22 1/2 NCT03287817 Followed by PD-1 antibody pembrolizumab 
CD19 NCT02706405 Followed by PD-1 antibody durvalumab 
CD19 1/2 NCT04257578 BTK inhibitor acalabrutinib prior 
CD20 1/2 NCT03277729  
CD22 NCT04088890  
TargetPhaseIdentifierAdditional agents
CD19/CD20 NCT04215016
NCT04007029 
 
CD19/CD22 NCT03233854  
CD19/CD22 1/2 NCT03287817 Followed by PD-1 antibody pembrolizumab 
CD19 NCT02706405 Followed by PD-1 antibody durvalumab 
CD19 1/2 NCT04257578 BTK inhibitor acalabrutinib prior 
CD20 1/2 NCT03277729  
CD22 NCT04088890  

BTK, Bruton’s tyrosine kinase inhibitor; PD-1, programmed death 1.

Close Modal

or Create an Account

Close Modal
Close Modal